Abstract
Cobicistat is a novel cytochrome P450 3A4 (CYP3A4) inhibitor in advanced clinical evaluation for use as a pharmacoenhancer of antiretroviral drugs. It lacks significant anti-HIV activity and is more selective than ritonavir in its enzyme inhibition. In addition, its water solubility may lend itself to coformulation with other drugs. Renal adverse effects and a considerable drug interaction potential limit its clinical utility and caution is required when using it. A fixed-dose combination product containing cobicistat in addition to elvitegravir, tenofovir and emtricitabine, and providing a one-pill, once-a-day antiretroviral regimen was recently approved.
Original language | English (US) |
---|---|
Pages (from-to) | 233-237 |
Number of pages | 5 |
Journal | Drugs of Today |
Volume | 49 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2013 |
Keywords
- Cobicistat
- Cytochrome P450 3A4 inhibitors
- GS-9350
- Pharmacoenhancer
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)